Replication FailureOpen accessMedicine· cited by 10

Transarterial chemoembolization plus atezolizumab and bevacizumab in patients with intermediate hepatocellular carcinoma: a single-arm, phase 2 trial

Kang Wang; Jinkai Feng; Hongming Yu; Yuqiang Cheng; Yanjun Xiang; Zonghan Liu; Yingyi Qin; Enyu Liu · 2025 · Signal Transduction and Targeted Therapy

WASTE classifies this as Replication Failure · AI classification, approximate

A previously reported effect did not replicate here — verify it holds before you build on it.

Abstract

Transarterial chemoembolization (TACE) is the standard treatment for intermediate-stage hepatocellular carcinoma (HCC), yet its efficacy as a standalone therapy remains suboptimal. This phase 2 trial (ChiCTR2100049829) evaluated the feasibility and safety of TACE combined with atezolizumab and bevacizumab in patients with intermediate-stage HCC. Participants received TACE followed by atezolizumab and bevacizumab until disease progression, unacceptable toxicity, or death. The primary endpoint was objective response rate (ORR) assessed per Response Evaluation Criteria in Solid Tumors (RECIST) v1

Abstract by Kang Wang; Jinkai Feng; Hongming Yu; Yuqiang Cheng; Yanjun Xiang; Zonghan Liu; Yingyi Qin; Enyu Liu, Signal Transduction and Targeted Therapy (2025) — licensed CC BY 4.0.

Read the full paper (open access)